Calling for improved translation in nanomedical research

The use of nanoparticles as novel diagnostic and therapeutic tools has gained immense attention in the field of cancer management. Nano-based therapies offer numerous possibilities such as enhanced drug solubility and stability, extended circulation times, tissue, cell, organelle-specific targeting, early detection and monitoring of diseases, stimuli-controlled drug release and co-delivery of multiple agents, all contributing to a safer drug delivery with minimized dose-limiting side-effects [1]. Several nanomedicines bearing these features are already on the market with many others following in the pipeline.